[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kyverna Therapeutics Inc (KYTX)

Kyverna Therapeutics Inc (KYTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 521,013
  • Shares Outstanding, K 60,795
  • Annual Sales, $ 0 K
  • Annual Income, $ -161,310 K
  • EBIT $ -164 M
  • EBITDA $ -162 M
  • 60-Month Beta 2.05
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.64

Options Overview Details

View History
  • Implied Volatility 99.53% (+12.82%)
  • Historical Volatility 97.98%
  • IV Percentile 13%
  • IV Rank 3.90%
  • IV High 547.61% on 07/07/25
  • IV Low 81.33% on 12/22/25
  • Expected Move (DTE 28) 1.62 (18.71%)
  • Put/Call Vol Ratio 106.00
  • Today's Volume 107
  • Volume Avg (30-Day) 489
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 7,930
  • Open Int (30-Day) 8,977
  • Expected Range 7.02 to 10.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.68
  • Number of Estimates 5
  • High Estimate $-0.62
  • Low Estimate $-0.72
  • Prior Year $-0.97
  • Growth Rate Est. (year over year) +29.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.25 +4.73%
on 04/29/26
11.15 -22.51%
on 05/13/26
-1.07 (-11.02%)
since 04/21/26
3-Month
7.34 +17.63%
on 03/30/26
11.62 -25.65%
on 04/20/26
+0.96 (+12.50%)
since 02/20/26
52-Week
2.19 +294.52%
on 05/22/25
13.67 -36.80%
on 12/15/25
+6.43 (+290.95%)
since 05/21/25

Most Recent Stories

More News
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer

EMERYVILLE, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune...

KYTX : 8.61 (+0.47%)
Kyverna Therapeutics to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with...

KYTX : 8.61 (+0.47%)
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results

Positive pre-BLA meeting with FDA alignment reached on KYSA-8 single-arm trial in stiff person syndrome (SPS); rolling BLA submission initiated Miv-cel pivotal trial primary analysis results in SPS...

KYTX : 8.61 (+0.47%)
Kyverna Therapeutics Earnings Call Could Reveal Whether Its Treg Platform Has Clinical Traction

Barchart Research What to Expect from KYTX Earnings KYTX Generated May 11, 2026 Current Price $10.34 EPS Estimate $$-0.75 Consensus Rating Strong Buy Average Move 8.31% Kyverna Therapeutics Earnings Call...

KYTX : 8.61 (+0.47%)
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer

EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with...

KYTX : 8.61 (+0.47%)
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting

Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS...

KYTX : 8.61 (+0.47%)
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks

100% of patients achieved rapid, sustained improvements across MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial  Totality of efficacy and safety data reinforces miv-cel’s...

KYTX : 8.61 (+0.47%)
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026

EMERYVILLE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients...

KYTX : 8.61 (+0.47%)
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026 Progressing enrollment...

KYTX : 8.61 (+0.47%)
Kyverna Therapeutics Faces Critical Test as Losses Mount Despite Recent Beats

Barchart Research What to Expect from KYTX Earnings KYTX Generated March 25, 2026 Current Price $7.87 EPS Estimate $-0.80 Consensus Rating Strong Buy Average Move 9.09% Kyverna Therapeutics Faces Critical...

KYTX : 8.61 (+0.47%)

Business Summary

Kyverna Therapeutics Inc. is a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. The company's lead product candidate includes KYV-101. Kyverna Therapeutics Inc. is based in EMERYVILLE, Calif.

See More

Key Turning Points

3rd Resistance Point 9.34
2nd Resistance Point 9.18
1st Resistance Point 8.87
Last Price 8.61
1st Support Level 8.41
2nd Support Level 8.25
3rd Support Level 7.94

See More

52-Week High 13.67
Fibonacci 61.8% 9.28
Last Price 8.61
Fibonacci 50% 7.93
Fibonacci 38.2% 6.58
52-Week Low 2.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.